Lexeo Therapeutics, Inc. (LXEO)
| Market Cap | 202.36M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -86.60M |
| Shares Out | 33.07M |
| EPS (ttm) | -3.13 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 231,562 |
| Open | 5.96 |
| Previous Close | 6.02 |
| Day's Range | 5.77 - 6.25 |
| 52-Week Range | 5.77 - 22.33 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 22.71 (+271.08%) |
| Earnings Date | Nov 13, 2024 |
About LXEO
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich’s ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic car... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for LXEO stock is "Strong Buy." The 12-month stock price forecast is $22.71, which is an increase of 271.08% from the latest price.
News
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression...
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact Underlying Genetic Cause of APOE4-Associated Alzheimer's
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference
NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular...
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascula...
Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights
Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrate...
Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further
Lexeo Therapeutics, Inc. achieved positive results across two studies using LX2006 for the treatment of patients with Friedreich's Ataxia Cardiomyopathy; Clinically meaningful improvements observed in...
Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet
U.S. stocks traded higher midway through trading, with the Nasdaq Composite rising more than 200 points on Monday.
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
Achieved mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months in participants with elevated LVMI at baseline
Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company, today announced the appointment of Tim Van Hauwermeiren, co-founder and ...
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
Closed an oversubscribed $95 million equity financing in March with Q1 2024 cash balance of $195.1 million at quarter-end, expected to provide runway into 2027 Completed in-license agreement with Corn...
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
Lexeo Therapeutics gains intellectual property rights including current and future clinical data from ongoing Weill Cornell Medicine investigator-initiated trial of gene therapy candidate AAVrh.10hFXN...
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy
NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascula...
Lexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Off
Lexeo Therapeutics, Inc. has results from its phase 1/2 SUNRISE-FA study, using LX-2006 for the treatment of patients with FA cardiomyopathy, expected in mid-2024. Results from all cohorts of phase 1/...
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascula...
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Lexeo announces $95.0M equity financing, which in addition to 2023 year-end cash and cash equivalents of $121.5M, extends runway to fund operations into 2027
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP, with participation from new and existing investors including RA Capital Management, Surveyor...
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
NEW YORK, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular...
Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic
Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights
Completed enrollment of the LEAD Phase 1/2 clinical trial of LX1001 for the treatment of APOE4-associated Alzheimer's disease Received clearance of LX2006 Clinical Trial Application (CTA) in Canada fo...
U.S. IPO Weekly Recap: Biotech Lexeo Stumbles After $100 Million IPO
Two IPOs are currently scheduled for the week ahead, although some small issuers may join the calendar late. As of 11/2/2023, the Renaissance IPO Index was up 23.5% year-to-date, while the S&P 500 was...
Lexeo Therapeutics' stock falls 15% in trading debut after its IPO priced below range
Lexeo Therapeutics Inc.'s stock LXEO, -15.01% tumbled 15% in its trading debut on Friday, after the company's initial public offering priced below the proposed price range. The stock priced at $11, be...
Lexeo Therapeutics Proposes Terms For $126 Million IPO
Lexeo Therapeutics, Inc. has filed to raise $126 million in an IPO, to support developing treatments for cardiovascular and Alzheimer's conditions. The company's lead candidate, LX2006, is in Phase 1/...
Lexeo Therapeutics Starts $100 Million U.S. IPO Effort
Lexeo Therapeutics, Inc. has filed for a $100 million IPO to develop treatments for cardiovascular and Alzheimer's conditions, although the final figure may differ. The company's lead candidate, LX200...